NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Other Prepaid Expenses and Other Current Assets

3 Months Ended

Dec. 31, 2021

3. Other Prepaid Expenses and Other Current Assets

The Company’s prepaid expenses and other current assets consisted of the following:


	As of December 31,		As of September 30,
	2021		2021
Prepaid research and development expense	$	453,706	$	583,267
Prepaid rent		—		172,518
Other prepaid expenses and other current assets		390,698		780,401
Total	$	844,404	$	1,536,186